We are pleased to announce the appointment of a new CEO to two of our core group of companies, KBI Biopharma, Inc. and Selexis S.A. We have asked Mr. Mark W. Womack, who has extensive experience in the CDMO and biologics business, to join our group.

For details, please see the announcement from JSR Life Sciences LLC.

https://news.jsrlifesciences.com/213674-jsr-life-sciences-appoints-veteran-biotech-and-cdmo-leader-mark-w-womack-to-lead-kbi-biopharma-and-selexis-sa